Cargando…

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa

Background: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV infection and is a recommended intervention for HIV-negative persons with substantial HIV risk.  Demonstration projects conducted in diverse settings worldwide illustrate practical examples of how PrEP can be deliver...

Descripción completa

Detalles Bibliográficos
Autores principales: Heffron, Renee, Ngure, Kenneth, Odoyo, Josephine, Bulya, Nulu, Tindimwebwa, Edna, Hong, Ting, Kidoguchi, Lara, Donnell, Deborah, Mugo, Nelly R., Bukusi, Elizabeth A., Katabira, Elly, Asiimwe, Stephen, Morton, Jennifer, Morrison, Susan, Haugen, Harald, Mujugira, Andrew, Haberer, Jessica E., Ware, Norma C., Wyatt, Monique A., Marzinke, Mark A., Frenkel, Lisa M., Celum, Connie, Baeten, Jared M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757790/
https://www.ncbi.nlm.nih.gov/pubmed/29355231
http://dx.doi.org/10.12688/gatesopenres.12752.2
_version_ 1783290891857821696
author Heffron, Renee
Ngure, Kenneth
Odoyo, Josephine
Bulya, Nulu
Tindimwebwa, Edna
Hong, Ting
Kidoguchi, Lara
Donnell, Deborah
Mugo, Nelly R.
Bukusi, Elizabeth A.
Katabira, Elly
Asiimwe, Stephen
Morton, Jennifer
Morrison, Susan
Haugen, Harald
Mujugira, Andrew
Haberer, Jessica E.
Ware, Norma C.
Wyatt, Monique A.
Marzinke, Mark A.
Frenkel, Lisa M.
Celum, Connie
Baeten, Jared M.
author_facet Heffron, Renee
Ngure, Kenneth
Odoyo, Josephine
Bulya, Nulu
Tindimwebwa, Edna
Hong, Ting
Kidoguchi, Lara
Donnell, Deborah
Mugo, Nelly R.
Bukusi, Elizabeth A.
Katabira, Elly
Asiimwe, Stephen
Morton, Jennifer
Morrison, Susan
Haugen, Harald
Mujugira, Andrew
Haberer, Jessica E.
Ware, Norma C.
Wyatt, Monique A.
Marzinke, Mark A.
Frenkel, Lisa M.
Celum, Connie
Baeten, Jared M.
author_sort Heffron, Renee
collection PubMed
description Background: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV infection and is a recommended intervention for HIV-negative persons with substantial HIV risk.  Demonstration projects conducted in diverse settings worldwide illustrate practical examples of how PrEP can be delivered. This manuscript presents estimates of effectiveness and patterns of PrEP use within a two-year demonstration project of PrEP for HIV-negative members of heterosexual HIV serodiscordant couples in East Africa. Methods: The PrEP delivery model integrated PrEP into HIV treatment services, prioritizing PrEP use for HIV-negative partners within serodiscordant couples before and during the first 6 months after the partner living with HIV initiated antiretroviral therapy (ART).  We measured PrEP uptake through pharmacy records and adherence to PrEP through medication event monitoring system (MEMS) bottle caps and quantification of tenofovir in plasma among a random sample of participants. We estimated HIV infections prevented using a counterfactual cohort simulated from the placebo arm of a previous PrEP clinical trial. Results: We enrolled 1,010 HIV serodiscordant couples that were naïve to ART and PrEP.  Ninety-seven percent of HIV-negative partners initiated PrEP. Objective measures suggest high adherence: 71% of HIV-negative participants took ≥80% of expected doses, as recorded via MEMS, and 81% of plasma samples had tenofovir detected.  Four incident HIV infections were observed (incidence rate=0.24 per 100 person-years), a 95% reduction (95% CI 86-98%, p<0.0001) in HIV incidence, relative to estimated HIV incidence for the population in the absence of PrEP integrated into HIV treatment services.   Conclusions: PrEP uptake and adherence were high and incident HIV was rare in this PrEP demonstration project for African HIV-negative individuals whose partners were known to be living with HIV.  Delivery of PrEP to HIV-negative partners within HIV serodiscordant couples was feasible and should be prioritized for wide-scale implementation.
format Online
Article
Text
id pubmed-5757790
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-57577902018-01-19 Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa Heffron, Renee Ngure, Kenneth Odoyo, Josephine Bulya, Nulu Tindimwebwa, Edna Hong, Ting Kidoguchi, Lara Donnell, Deborah Mugo, Nelly R. Bukusi, Elizabeth A. Katabira, Elly Asiimwe, Stephen Morton, Jennifer Morrison, Susan Haugen, Harald Mujugira, Andrew Haberer, Jessica E. Ware, Norma C. Wyatt, Monique A. Marzinke, Mark A. Frenkel, Lisa M. Celum, Connie Baeten, Jared M. Gates Open Res Research Article Background: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV infection and is a recommended intervention for HIV-negative persons with substantial HIV risk.  Demonstration projects conducted in diverse settings worldwide illustrate practical examples of how PrEP can be delivered. This manuscript presents estimates of effectiveness and patterns of PrEP use within a two-year demonstration project of PrEP for HIV-negative members of heterosexual HIV serodiscordant couples in East Africa. Methods: The PrEP delivery model integrated PrEP into HIV treatment services, prioritizing PrEP use for HIV-negative partners within serodiscordant couples before and during the first 6 months after the partner living with HIV initiated antiretroviral therapy (ART).  We measured PrEP uptake through pharmacy records and adherence to PrEP through medication event monitoring system (MEMS) bottle caps and quantification of tenofovir in plasma among a random sample of participants. We estimated HIV infections prevented using a counterfactual cohort simulated from the placebo arm of a previous PrEP clinical trial. Results: We enrolled 1,010 HIV serodiscordant couples that were naïve to ART and PrEP.  Ninety-seven percent of HIV-negative partners initiated PrEP. Objective measures suggest high adherence: 71% of HIV-negative participants took ≥80% of expected doses, as recorded via MEMS, and 81% of plasma samples had tenofovir detected.  Four incident HIV infections were observed (incidence rate=0.24 per 100 person-years), a 95% reduction (95% CI 86-98%, p<0.0001) in HIV incidence, relative to estimated HIV incidence for the population in the absence of PrEP integrated into HIV treatment services.   Conclusions: PrEP uptake and adherence were high and incident HIV was rare in this PrEP demonstration project for African HIV-negative individuals whose partners were known to be living with HIV.  Delivery of PrEP to HIV-negative partners within HIV serodiscordant couples was feasible and should be prioritized for wide-scale implementation. F1000 Research Limited 2018-01-30 /pmc/articles/PMC5757790/ /pubmed/29355231 http://dx.doi.org/10.12688/gatesopenres.12752.2 Text en Copyright: © 2018 Heffron R et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Heffron, Renee
Ngure, Kenneth
Odoyo, Josephine
Bulya, Nulu
Tindimwebwa, Edna
Hong, Ting
Kidoguchi, Lara
Donnell, Deborah
Mugo, Nelly R.
Bukusi, Elizabeth A.
Katabira, Elly
Asiimwe, Stephen
Morton, Jennifer
Morrison, Susan
Haugen, Harald
Mujugira, Andrew
Haberer, Jessica E.
Ware, Norma C.
Wyatt, Monique A.
Marzinke, Mark A.
Frenkel, Lisa M.
Celum, Connie
Baeten, Jared M.
Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
title Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
title_full Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
title_fullStr Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
title_full_unstemmed Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
title_short Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa
title_sort pre-exposure prophylaxis for hiv-negative persons with partners living with hiv: uptake, use, and effectiveness in an open-label demonstration project in east africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757790/
https://www.ncbi.nlm.nih.gov/pubmed/29355231
http://dx.doi.org/10.12688/gatesopenres.12752.2
work_keys_str_mv AT heffronrenee preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT ngurekenneth preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT odoyojosephine preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT bulyanulu preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT tindimwebwaedna preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT hongting preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT kidoguchilara preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT donnelldeborah preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT mugonellyr preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT bukusielizabetha preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT katabiraelly preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT asiimwestephen preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT mortonjennifer preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT morrisonsusan preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT haugenharald preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT mujugiraandrew preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT habererjessicae preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT warenormac preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT wyattmoniquea preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT marzinkemarka preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT frenkellisam preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT celumconnie preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT baetenjaredm preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica
AT preexposureprophylaxisforhivnegativepersonswithpartnerslivingwithhivuptakeuseandeffectivenessinanopenlabeldemonstrationprojectineastafrica